A Study of SGB-7342 in Subjects With Obesity or Overweight

Starting soon · Phase 1 · Has a placebo group

Conditions studied: Obesity & Overweight

In brief

The purpose of this study is to evaluate the safety and tolerability of subcutaneously administered SGB-7342 in adult subjects with obesity and overweight.

Key facts

Study ID

NCT07324850

Run by

Suzhou Sanegene Bio Inc.

People needed

45

Starts

2026-01-12

Expected to finish

2027-04-14

Last updated by the study team

2026-01-09

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Body Mass Index (BMI) within the range of 26.0 to 35.0 kg/m²
• Have a stable body weight within 3 months
• Participants must agree to use adequate contraception from signing the informed consent until 6 months after completion of the follow-up visit.
• Willing to comply with the protocol required visit schedule and visit requirements and provide written informed consent.

You may not qualify if…

• A history of or a current surgical or medical condition that, in the opinion of the Investigator, may put the subject at significant risk (according to Investigator's judgment) or interfere with the subject's participation in the clinical study.
• Use of GLP-1R agonists for any indication within 6 months prior to administering the investigational drug.
• Use of non-GLP1R medications for weight loss within 3 months prior to administering the investigational drug.
• Alanine aminotransferase (ALT), total bilirubin (TBIL), aspartate aminotransferase (AST)> 1.5 × ULN, and deemed clinically significant by the Investigators

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.